Consensus Susceptibility in the ATLAS Framework: Cross-Tumour Agreement, Distributional Concordance and Categorical Stability
Description
Consensus Susceptibility in the ATLAS Framework: Cross-Cancer Agreement, Pairwise Concordance and Categorical Heterogeneity
This working paper presents a structured cross-cancer evaluation of categorical anticancer susceptibility within the ATLAS framework. The study examines whether susceptibility patterns assigned to individual active anticancer molecular forms (AACFs) are shared across distinct cancer-type groups and how strongly those patterns are concentrated, concordant, or context-dependent.
The analysis is based on the validated ATLAS computational dataset comprising 97 AACFs, 1,999 cancer cell-line records, 32 cancer-type groups, and 193,902 observed susceptibility predictions. In contrast to pooled cell-line analysis, the present study treats each cancer-type group as an equally weighted analytical context, thereby preventing groups with larger numbers of cell-line records from dominating the cross-cancer interpretation.
Five complementary tests are implemented:
- Exact cross-cancer zone consensus, evaluating agreement in the dominant six-zone ATLAS susceptibility classification;
- Favourable-domain cross-cancer consensus, assessing broader directional agreement across favourable and non-favourable categorical domains;
- Conditional pairwise cross-cancer concordance, quantifying agreement and categorical distance between cancer-type groups with uniquely defined dominant zones;
- Cross-cancer heterogeneity and consensus entropy, measuring categorical dispersion using normalized Shannon entropy and related concentration statistics;
- Integrated cross-cancer consensus profiling, combining susceptibility direction, structural consensus, and local discordance into a multidimensional categorical interpretation.
The results demonstrate that cross-cancer susceptibility patterns within ATLAS are frequently structured rather than diffusely heterogeneous. Thirty-one AACFs show complete exact-zone consensus across all 32 cancer-type groups, 42 exhibit zero normalized entropy together with 100% conditional pairwise exact agreement among uniquely classified groups, and 43 show favourable cross-cancer domain consensus. Twenty AACFs are universally favourable across all cancer-type groups.
The integrated analysis identifies 46 AACFs with Tier A very high structural consensus, including 17 favourable and 29 non-favourable profiles. Nineteen favourable AACFs reach either Tier A or Tier B structural consensus. These findings demonstrate that structural consensus is direction-neutral and should be distinguished from susceptibility direction itself.
The study extends the methodological evaluation initiated in Working Paper No. 1. Whereas the first working paper evaluates whether categorical susceptibility assignments remain stable under perturbation, the present study evaluates whether those assignments are shared across distinct tumour contexts. Robustness and consensus are therefore treated as complementary but non-equivalent properties.
All analyses are fully reproducible and are distributed as a FAIR-oriented research package containing the validated ATLAS.db SQLite database, executable Wolfram Language scripts, complete textual outputs, machine-readable results, and a graphical abstract with associated metadata.
The reported findings describe computational categorical coherence within the ATLAS framework. They do not constitute evidence of experimentally confirmed anticancer activity, pharmacological efficacy, therapeutic benefit, or clinical effectiveness. The principal role of the present study is methodological: to identify broadly shared, heterogeneous, and context-dependent susceptibility structures and to provide a reproducible basis for future experimental prioritization and validation.
Notes
Files
Tsanov_Consensus_Susceptibility_in_the_ATLAS.pdf
Additional details
References
- Tsanov, V., Tsanov, H. ATLAS — An Interpretable Reference Atlas for Transcriptome-Guided Prioritization of Active Anticancer Molecular Forms De- rived from Natural Nitrile Glycosides. Third supplemented edition, 2026. Zenodo. DOI: 10.5281/zenodo.22016797.
- Manica, M., Oskooei, A., Born, J., Subramanian, V., Sáez-Rodríguez, J., Ro- dríguez Martínez, M. Toward explainable anticancer compound sensitivity predic- tion via multimodal attention-based convolutional encoders. Molecular Pharma- ceutics, 16(12), 4797–4806, 2019. DOI: 10.1021/acs.molpharmaceut.9b00520.
- Cadow, J., Born, J., Manica, M., Oskooei, A., Rodríguez Martínez, M. PaccMann: a web service for interpretable anticancer compound sensitivity prediction. Nucleic Acids Research, 48(W1), W502–W508, 2020. DOI: 10.1093/nar/gkaa327
- Barretina, J., Caponigro, G., Stransky, N., et al. The Cancer Cell Line Ency- clopedia enables predictive modelling of anticancer drug sensitivity. Nature, 483, 603–607, 2012. DOI: 10.1038/nature11003
- Garnett, M. J., Edelman, E. J., Heidorn, S. J., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature, 483, 570–575, 2012. DOI: 10.1038/nature11005
- Iorio, F., Knijnenburg, T. A., Vis, D. J., et al. A landscape of pharmacogenomic interactions in cancer. Cell, 166(3), 740–754, 2016. DOI: 10.1016/j.cell.2016.06.017.
- Ghandi, M., Huang, F. W., Jané-Valbuena, J., et al. Next-generation character- ization of the Cancer Cell Line Encyclopedia. Nature, 569, 503–508, 2019. DOI: 10.1038/s41586-019-1186-3.
- Tsherniak, A., Vazquez, F., Montgomery, P. G., et al. Defining a cancer dependency map. Cell, 170(3), 564–576.e16, 2017. DOI: 10.1016/j.cell.2017.06.010.
- Chiu, Y.-C., Zheng, S., Wang, L.-J., et al. Predicting and characterizing a cancer dependency map of tumors with deep learning. Science Advances, 7(34), eabh1275, 2021. DOI: 10.1126/sciadv.abh1275.
- Shannon, C. E. A mathematical theory of communication. Bell System Technical Journal, 27(3), 379–423, 1948. DOI: 10.1002/j.1538-7305.1948.tb01338.x.
- Shannon, C. E. A mathematical theory of communication. Bell System Technical Journal, 27(4), 623–656, 1948. DOI: 10.1002/j.1538-7305.1948.tb00917.x
- Simpson, E. H. Measurement of diversity. Nature, 163, 688, 1949. DOI: 10.1038/163688a0
- Efron, B., Tibshirani, R. J. An Introduction to the Bootstrap. Chapman & Hall/CRC, New York, 1993. DOI: 10.1007/978-1-4899-4541-9.
- Benjamini, Y., Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B, 57(1), 289–300, 1995. DOI: 10.1111/j.2517-6161.1995.tb02031.x.
- Wilkinson, M. D., Dumontier, M., Aalbersberg, I. J., et al. The FAIR Guiding Prin- ciples for scientific data management and stewardship. Scientific Data, 3, 160018, 2016. DOI: 10.1038/sdata.2016.18.
- Wolfram Research, Inc. Mathematica, Version 14.3. Champaign, Illinois: Wolfram Research, Inc., 2025.
- Wolfram Research, Inc. Wolfram Language & System Documentation Center. Wol- fram Research, Inc.